Free tool
FAERS Monitor: Zestoretic
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019888 or its brand name (Zestoretic, Hydrochlorothiazide, Lisinopril). Reports on generic versions are filed under their own applications.
Reports
10,267
Serious
6,201
60% of reports
Hospitalization
3,320
Death reported
596
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea692
- fatigue684
- diarrhoea618
- drug ineffective577
- pain505
- dizziness498
- dyspnoea444
- headache438
- asthenia372
- vomiting357
- cough354
- arthralgia341
- fall334
- hypertension326
- malaise314
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 174 |
| 2005 | 178 |
| 2006 | 210 |
| 2007 | 230 |
| 2008 | 312 |
| 2009 | 501 |
| 2010 | 786 |
| 2011 | 771 |
| 2012 | 726 |
| 2013 | 175 |
| 2014 | 440 |
| 2015 | 833 |
| 2016 | 581 |
| 2017 | 430 |
| 2018 | 553 |
| 2019 | 474 |
| 2020 | 530 |
| 2021 | 449 |
| 2022 | 417 |
| 2023 | 410 |
| 2024 | 355 |
| 2025 | 440 |
| 2026 | 292 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,043,892 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hypertensionSignal | 326 | 3.2 | 2.8 | 482 |
| coughSignal | 354 | 2.6 | 2.3 | 348 |
| fallSignal | 334 | 2.1 | 1.9 | 183 |
| dizzinessSignal | 498 | 2.0 | 1.9 | 272 |
| astheniaSignal | 372 | 2.0 | 1.8 | 196 |
| diarrhoea | 618 | 2.0 | 1.8 | 300 |
| fatigue | 684 | 1.8 | 1.7 | 252 |
| nausea | 692 | 1.8 | 1.7 | 251 |
| pain | 505 | 1.7 | 1.5 | 144 |
| arthralgia | 341 | 1.7 | 1.5 | 95 |
| dyspnoea | 444 | 1.6 | 1.5 | 104 |
| vomiting | 357 | 1.6 | 1.4 | 72 |
| malaise | 314 | 1.5 | 1.3 | 47 |
| headache | 438 | 1.4 | 1.3 | 58 |
| drug ineffective | 577 | 0.9 | 0.8 | 7 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.